NYCDoc29
@nycdoc29ASCO, ASH, EHA & ESMO Member - fr FT academic, traveller, foodie & now private practice! #girldad #boydad #hematology #oncology
Similar User
@DrHedrick
@hemedoc
@DrJFriedberg
@drjoannarhodes1
@LiaPalomba
@OmidHamidMD
@PLMcCarthyMD
@mtmdphd
@EagleMyeloma
@TapKadia
@DrJulieVose
@rajshekharucms
@RielyMD
@rsm2800
@MaurerStats
CONGRESS #EHA2024 | Primary analysis of the phase II ELM-2 study demonstrates deep and durable responses with odronextamab (CD20×CD3 bispecific antibody) in heavily pretreated pts with R/R FL. Primary endpoint ORR, 80%; CR rate 73%; CR correlated with favorable PFS and OS at 24…
Impressive PFS with the quadruplet combination in NTEMM…but balancing efficacy and tolerability is key in the elderly. Great plenary presentation by Prof Facon #EHA2024
Galtier - outcome of PMBCL with CAR-T (Descar-T data) - 55 axi-cel pts - 80% CMR - 2y PFS 68.7% - CRP > 30 prognostic - LDH / briding response NOT prognostic Excellent outcomes! Encouraging. #EHA2024 #lymsm
CONGRESS #EHA2024 | Arnon P. Kater @amsterdamumc shared early results of the EPCORE CLL-1 trial of epcortitamab in Richter's transformation (RT). N=35, mFU=8.1 mo, ORR was 53% (60% & 44% in 1L RT & 2L RT, resp), CR rate was 42% (50% & 33% in 1L RT & 2L RT, resp), OS was 11.7 mo,…
Glofitamab monotherapy as salvage therapy in heavily pretreated mantle cell #lymphoma With @amniebla as chair-@WomenInLymphoma of the session! 💪 @geltamo #EHA2024
First results of BMS-986393 GPRC5D CAR T-Cells in 1-3 prior lines of therapy presented at #EHA2024 ORR 96%, CR 42% Low rates of dysgeusia/nail/skin changes 55% triple class refractory pts, 29% EMD Median 2 prior lines of therapy 87% of responses ongoing #mmsm
#EHA24, Bories Pierre Real world data on elderly>75 with CAR-t versus younger.<75 Bias of selection likely but as good as for younger. So we can treat also the old 😊 increased risk of infections!!
Do check out our multicentre collaboration from 🇨🇦 at #EHA24 👍🏼 Belumosudil shows promise in treating patients with heavily pre-treated moderate-severe cGVHD. Median of 5 prior lines of Rx (all Rux exposed) Median of 3 affected organs at start of Rx FFS 6m: 72% #EHA24
Important updates to MANIFEST 2 presented by @RaajitRampal at #EHA24 beyond what was presented at #ASH23 @bose_prithviraj @harrisoncn1 #johnmascarenhas @Vikas_Gupta_1 @KuykendallMd @AaronGerds @mpdrc @mpndoc @pankitvachhani
👉👉👉Honored to present #EHA24 #EHA2024 today 👉#TRANSFORM-1 results randomized ph3 clinical trial. RUXO+#NAVITOCLAX frontline vs RUXO+placebo n=252, Med f/u 20.3 mo. SVR35w24= 63.2% NaV+RuXo vs 31.5% in RUXO+PLCBO ➡️Primary Endpoint met| #MPNSM @EHA_Hematology @harrisoncn1
Always nice to see long-term follow up results! Dr. Moreau pointed out that >80% of patients in Dara-VTD arm of CASSIOPEIA are alive at 8 years despite half of them getting no maintenace! Exciting prospects indeed for limited duration therapy in #MultipleMyeloma! #EHA24
#EHA2024 #EHA24 #MPN_PV Palandri: state of the art talk on PV 1) 4 must-dos in all pts. 2) timely intervention, moving to 2nd line therapy appropriately, nice algorithm 👇🏽 3) Role of hepcidin analogues.
#MedTwitter - licensing currently is state issued & controlled by state boards which are highly political. Nobody wants to ceed their fief & governors don't want to lose control. #telehealth
📣📣📣 We need permanent #telehealth coverage & either a single national license or universal interstate reciprocity of licensure for clinicians now! #MedTwitter #NurseTwitter & patients, call your Congresspeople & tell them you want this: 202-224-3121.
LAURA Ph 3: Osimertinib vs Placebo #ASCO24 @ASCO ➡️ mPFS: 39.1 vs 5.6 mo (HR 0.16) ‼️ ➡️ 24-mo PFS: 65% vs 13% 📈 ➡️ 81% received osi at progression 💊, Good! ➡️AE discontinuation**: 13% vs 5% ⚠️ Can't wait for @RamalingamMD's presentation today! 🎤 #ASCO24 @OncoAlert Data…
Antonio Giordano (@antgiorda) from @DFCI_BreastOnc presents the first data of the Nectin4 ADC enfortumab vedotin in metastatic breast cancer. ORR 15.6% in HR+ and 19% in TNBC, PFS 5.4 and 3.5 months, respectively. Nectin4 expression not predictive of benefit with EV. #ASCO24
#ASCO24 DESTINY-Breast07: T-DXd and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC (phase 1b/2) First-line!!!! ORR T-DXD➡️76% T-DXd +P➡️84% 1y PFS➡️80.8% and 89.4% Presented by Prof @FAndreMD @OncoAlert
#ASCO24 very impressive BUT depending on program structure & state this "gift card" maybe viewed as "inducement" & run afoul against state or insurer "anti-kickback" regulation. States NEED to address this immediately. #foodinsecurity #patientsfirst @fumikochino @manalipatelmd
🍎Loved this simple intervention ($40 monthly grocery store gift cards redeemable at local retailers x 6 mo). It decreased #foodinsecurity & improved quality of life. Turns out that just helping people meet their essential needs improves life for people with cancer. #ASCO24
👏KRAS IS POTENTIALLY DRUGGABLE IN PANCREATIC ADENOCARCINOMA 👏 But that means overcoming therapeutic nihilism and also performing the molecular testing that can surface an actionable mutation Once again, the oncologist without the pathologist is blind! #pancsm #ASCO24
PostMonarch: Abemaciclib after progression on CDK4/6 inhib shows 27% reduction in PFS. All subgroups, all biomarkers seem to benefit. Valuable in the current landscape; sets the stage for EMBER-3 w/oral SERD + CDK4/6 and allows maximal ET in MBC #ASCO24 @OncoAlert (COI/author)
United States Trends
- 1. Chiefs 118 B posts
- 2. Mahomes 24,8 B posts
- 3. Brock Bowers 7.206 posts
- 4. #LVvsKC 9.426 posts
- 5. Antonio Pierce 1.880 posts
- 6. Carlson 18,7 B posts
- 7. Jeanty 17,8 B posts
- 8. Heisman 21,8 B posts
- 9. Black Friday 794 B posts
- 10. Kelce 17,3 B posts
- 11. Wanya Morris 1.621 posts
- 12. Andy Reid 2.152 posts
- 13. Aidan O'Connell 1.624 posts
- 14. Worst 11-1 1.348 posts
- 15. Luckiest 6.845 posts
- 16. Tommy Edman 5.964 posts
- 17. 2020 Steelers N/A
- 18. Hawks 14,9 B posts
- 19. hailee 14,2 B posts
- 20. Pacheco 13,8 B posts
Who to follow
-
David Hedrick he/him
@DrHedrick -
Aaron Logan, MD, PhD, MPhil
@hemedoc -
Jonathan Friedberg
@DrJFriedberg -
Joanna M. Rhodes, MD, MSCE
@drjoannarhodes1 -
Lia Palomba
@LiaPalomba -
Omid Hamid MD
@OmidHamidMD -
Philip McCarthy
@PLMcCarthyMD -
Mike Thompson, MD, PhD, FASCO
@mtmdphd -
Craig Hofmeister
@EagleMyeloma -
Tapan Kadia
@TapKadia -
Julie Vose
@DrJulieVose -
Raj Chakraborty
@rajshekharucms -
Gʀᴇɢᴏʀʏ Rɪᴇʟʏ
@RielyMD -
Robert S Miller, MD, FACP, FASCO, FAMIA-he/him
@rsm2800 -
Matthew J. Maurer, DMSc
@MaurerStats
Something went wrong.
Something went wrong.